D’Agostino, Mattia
Larocca, Alessandra http://orcid.org/0000-0002-2070-3702
Offidani, Massimo
Liberati, Anna Marina http://orcid.org/0000-0002-3686-3188
Gaidano, Gianluca
Petrucci, Maria Teresa
Derudas, Daniele http://orcid.org/0000-0002-0997-4157
Capra, Andrea
Zambello, Renato http://orcid.org/0000-0002-8799-5324
Cascavilla, Nicola
de Fabritiis, Paolo
Innao, Vanessa
Bonello, Francesca
Patriarca, Francesca
Benevolo, Giulia
Giuliani, Nicola http://orcid.org/0000-0003-3457-3774
Aitoro, Gabriele
Guglielmelli, Tommasina
Di Raimondo, Francesco
Corradini, Paolo http://orcid.org/0000-0002-9186-1353
Musto, Pellegrino
Hájek, Roman http://orcid.org/0000-0001-6955-6267
Sonneveld, Pieter
Boccadoro, Mario http://orcid.org/0000-0001-8130-5209
Bringhen, Sara http://orcid.org/0000-0003-4539-6363
Article History
Received: 11 January 2021
Revised: 15 March 2021
Accepted: 29 March 2021
First Online: 12 April 2021
Conflict of interest
: M.D. has received honoraria for lectures from Sanofi and GSK; has served on the advisory boards for GSK. A.L. has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and GSK; has served on the advisory boards for Bristol-Myers Squibb, Celgene, Janssen, and Takeda. M.O. has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, GSK, Sanofi, and Takeda; has served on the advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, GSK, Sanofi, and Takeda. A.M.L. has received personal fees from Incyte; has received research funding from Novartis, Janssen, AbbVie, Roche, Celgene, Amgen, Bristol-Myers Squibb, Takeda, Incyte, Pfizer, Beigene, Oncopeptides, Verastem, Karyopharm, Archigen, Biopharma, Debiopharm, Morphosys, Fibrogen, and Onconova. G.G. has served on the advisory boards for Janssen, AbbVie, and AstraZeneca; has served on the speaker’s bureaus for Janssen and AbbVie. M.T.P. has received honoraria from and served on the advisory boards for Celgene, Janssen-Cilag, Amgen, Bristol-Myers Squibb, Takeda, Sanofi, and GSK. R.Z. has served on the advisory boards for Janssen and Celgene. F.P. has served on the advisory boards for Celgene and Janssen. G.B. has received honoraria from Novartis, Celgene Amgen, and Takeda. N.G. has received research grants from Celgene and Janssen Pharmaceutica; has received sponsorship for clinical studies from Janssen Pharmaceutica, Millennium Pharmaceuticals, and GSK; has served on the advisory boards for Celgene, Takeda, and Janssen Pharmaceutica; has received support for participating in meetings from Janssen Pharmaceutica, Celgene, and Bristol-Myers Squibb. F.D.R. has received honoraria from Celgene, Janssen, Amgen, and Takeda. P.C. has participated as a lecturer and/or has served on the advisory boards for AbbVie, ADC Therapeutics, Amgen, Celgene, Daiichi Sankyo, Gilead, Incyte, Janssen, Jazz Pharmaceuticals, Kite, Kyowa Kirin, Novartis, Roche, Sanofi, Servier, and Takeda. P.M. has received honoraria and/or served on the scientific advisory boards for Celgene, Janssen, Takeda, Bristol-Myers Squibb, Amgen, Novartis, Gilead, Jazz, Sanofi, AbbVie, and Glaxo-Smith-Kline. R.H. has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda. P.S. has served on the advisory boards for Amgen, Celgene, Genenta, Janssen, Seattle Genetics, Takeda, and Karyopharm. M.B. has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie; has served on the advisory boards for Janssen and GSK; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma. S.B. has received honoraria from Celgene, Amgen, Janssen, and Bristol-Myers Squibb; has served on the advisory boards for Celgene, Amgen, Janssen, and Karyopharm; has received consultancy fees from Janssen and Takeda. The remaining authors declare no competing interests.